Article

Bacterial building resistance to moxifloxacin

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers.

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers, according to Gita Sathpathy and co-workers at the All India Institute of Medical Sciences, New Dehli, India.

The records of 934 consecutive cases of bacterial corneal ulcers were retrospectively reviewed and culture and antibiotic sensitivity reports of corneal scrapings were analysed. Recorded parameters included age, sex, organism isolated and sensitivity, using Kirby-Bauer disc-diffusion, to moxifloxacin. The bacterial isolates that were resistant to moxifloxacin were examined in detail and their antibiotic sensitivity to other drugs was studied.

Of the 934 bacterial isolates, 913 (97.5%) were sensitive to moxifloxacin and 21 (2.25%) were found to be resistant. Of the 21 resistant isolates, eight were Staphylococcus albus, eight were Pseudomonas, two were Streptococcus viridians, one was Streptococcus pneumoniae, one was Staphylococcus aureus and one was E. coli. Of the eight Pseudomonas cases, six were found to be sensitive to polymyxin and five sensitive to amikacin. Out of the eight Staphylococcus, seven were sensitive to vancomycin.

The emergence of a resistance to moxifloxacin in bacteria isolated from corneal ulcers, indicates that the drug should not be used indiscriminately.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.